Citations

Clear

35 citation(s) found for "Tibbo, Meagan".

A modified Delphi consensus on periprosthetic infection in orthopaedic oncology
Botello, Eduardo , Boyle, Richard A. , Morgan‐Jones, Rhidian , Laitinen, Minna , Lazarides, Alexander L. , Couch, Cory , Rose, Peter, Sullivan, Mikaela, Tibbo, Meagan, Laitinen, Minna K , Jeys, Lee , Ebeid, Walid , Houdek, Matthew T. , Kurisunkal, Vineet , Morris, Guy V , Puri, Ajay , Ruggieri, Pietro

Mayo Clinic

The Bone & Joint Journal | December 1, 2025 | Volume: 107-B | Issue: 12 | Pages: 1352-1359

10.1302/0301-620x.107b12.bjj-2024-1039.r4 | PMID 41319695 Get It

Aims The aim of this study was to achieve consensus for important topics related to periprosthetic infection (PJI) in orthopaedic oncology, and to identify areas for future research. Methods In January 2024, the Birmingham Orthopaedic Oncology Meeting (BOOM) held in Birmingham, UK, gathered 309 delegates from 53 countries to debate 20 consensus statements on PJI in orthopaedic oncology using a modified Delphi process. Results Of 20 questions and statements on PJI in orthopaedic oncology, none achieved unanimous consensus, 18 achieved strong consensus, one achieved moderate consensus, and one achieved weak consensus. The statements that reached consensus with notable agreement were on the prophylaxis of infection, management of leaking wounds, and surgical strategies for the treatment of PJI. Short-duration antibiotic prophylaxis was deemed as effective as longer courses for lower-risk reconstructions, and aggressive management was recommended for wounds draining beyond five to seven days to prevent deep infection. Furthermore, single-stage, two-stage, and 1.5-stage revision were recognized as valid strategies, with two-stage revision remaining the most reliable. The statements that did not achieve consensus were on the role of debridement, antibiotics, and implant retention and prolonged antibiotic use post-revision. Conclusion The BOOM meeting achieved consensus for important topics on periprosthetic infection in orthopaedic oncology, but highlighted the low quality of the underlying evidence. This study has provided recommendations for the treatment of leaky wounds, duration of postoperative antibiotic prophylaxis, and choice of revision strategy. Cite this article: Bone Joint J 2025;107-B(12):1352–1359.
Prospective clinical trial analyzing serum mast cell tryptase levels and arthrofibrosis rates after total knee arthroplasty
Meißner, Nils , Tibbo, Meagan E. , Berry, Daniel J. , Larson, Dirk R. , Sanchez-Sotelo, Joaquin, Meissner, Nils , Berry, Daniel J , Morrey, Mark E. , Sánchez‐Sotelo, Joaquín , Hannon, Charles P. , Abdel, Matthew P.

Mayo Clinic

Bone & Joint Research | November 19, 2025 | Volume: 14 | Issue: 11 | Pages: 1045-1052

10.1302/2046-3758.1411.bjr-2025-0108.r1 | PMID 41253179 Get It

Aims Arthrofibrosis affects a notable percentage of patients after total knee arthroplasty (TKA). Elevated serum mast cell tryptase (SMCT) levels have been linked to fibrosis, suggesting that SMCT could serve as a biomarker for arthrofibrosis. As such, the aims of this study were to assess SMCT levels in TKA patients, and their possible association with arthrofibrosis and clinical outcomes in a prospective clinical trial. Methods We conducted a prospective study involving 219 patients undergoing primary TKA at a single academic medical centre between January 2018 and December 2022. SMCT levels were measured preoperatively, immediately postoperatively, and at six weeks, three months, and one year postoperatively. Secondary outcomes included revision rates, complications, and Knee Society Scores (KSSs). Allergic and inflammatory conditions were assessed for their influence on SMCT levels. Results At one year postoperatively, eight patients had developed arthrofibrosis (4%), and three (1.5%) had undergone manipulation under anaesthesia. The mean preoperative SMCT level was 5.6 µg/L (SD 3.4), which decreased significantly to 4.1 µg/L (SD 2.7) immediately postoperatively (p < 0.001). At six weeks the mean SMCT level was 6.4 µg/l (SD 4.1), and was 6.1 µg/l at both three months (SD 4.1) and one year (SD 4.0). Elevated preoperative SMCT levels were not significantly associated with the risk of arthrofibrosis development (OR 3; p = 0.370), nor were immediate postoperative levels (OR 2; p = 0.754) or those at six weeks (OR 1; p = 0.989). Of note, elevated SMCT levels at three months (OR 5; 95% CI 0.4 to 64; p = 0.191) and one year (OR 13; 95% CI 1 to 232; p = 0.077) trended toward an increased risk of arthrofibrosis development, without reaching significance. Conclusion In patients undergoing TKA, with the numbers included in this study, there was no significant difference in SMCT levels between patients who did and did not develop arthrofibrosis at any timepoint. However, there was a trend towards elevated SMCT levels at three months and one year in those who developed arthrofibrosis, which merits further study. Cite this article: Bone Joint Res 2025;14(11):1045–1052.
Medicaid Reimbursement for Orthopedic Oncology Procedures Is Over 22% Lower Than Medicare and Highly Inconsistent Among States
Adám, H , Moore, M. Lane, Sullivan, Georgia , Braithwaite, Collin , Lin, Eugenia , Goulding, Krista , Tibbo, Meagan E. , Adam, Henderson , Sullivan, Georgia R, Braithwaite, Collin L, Goulding, Krista , Braithwaite, Collin L , Koschmeder, Katelyn

Mayo Clinic

Journal of Surgical Oncology | July 15, 2025 | Volume: 132 | Issue: 4 | Pages: 736-753

10.1002/jso.70042 | PMID 40662503 Get It

ABSTRACTBackground and ObjectivesMedicaid reimbursement to physicians has been demonstrated to be lower than reimbursement from Medicare and private insurance. Studies on Medicaid reimbursement for orthopedic oncology procedures, however, are limited. This study compares Medicaid reimbursement rates to Medicare for 38 common musculoskeletal oncology procedures and assesses variability among states.MethodsWe collected 38 current procedural terminology (CPT) codes for commonly performed orthopedic oncology procedures. Medicare rates were obtained from the 2023 Centers for Medicare and Medicaid physician (CMS) fee schedule. Medicaid rates were collected from electronic state website fee schedules. Reimbursement for the two insurance types were compared with state and national averages. Dollar differences were adjusted for work relative value units (RVU) to ascertain procedural variability. The Medicare Wage Index, representing differences in wages across states, was used to adjust medicaid rates to compare more accurately to medicare. Coefficient of variation values, calculated by dividing the standard deviation by the mean, were calculated to assess variation among procedures.ResultsMedicaid reimbursed orthopedic oncologists 22.1% less than medicare on average, increasing to 33.0% when adjusting for wage differences. State Medicaid reimbursement ranged from 37% to 131% of Medicare, with 38 states reimbursing less than Medicare on average. The coefficient of variation for Medicaid procedures ranged from 0.24 to 0.46, indicating wide variability among states and procedures, while for Medicare, the coefficient of variation was low at 0.06 to 0.07.ConclusionsMedicaid reimbursement for common orthopedic oncology procedures is substantially lower and more variable than Medicare, despite the often urgent nature of these surgeries. Disparities in reimbursement may impact access to care for this population, highlighting the need for policy reform.
Rare Extra‐Axial Chordoma of the Anteromedial Thigh: A Case Report
Tibbo, Meagan E. , Mysore, Nishad , Jose, Jean , Temple, H. Thomas , Rosenberg, Andrew E.

Mayo Clinic

Clinical Case Reports | April 23, 2025 | Volume: 13 | Issue: 4 | Pages: No page available

10.1002/ccr3.70341 | PMID 40270777 Get It

ABSTRACT Chordomas are rare notochordal malignancies typically occurring in the axial skeleton. Less than 100 extra‐axial chordomas have been reported. We describe a unique chordoma of the anteromedial thigh. The clinical presentation of extra‐axial chordomas is highly variable; thus, recognizing this entity in the differential diagnoses of extra‐axial bone/soft tissue tumors is important.
Identifying consensus and areas for future research in chondrosarcoma
Kurisunkal, Vineet , Botello, Eduardo , Boyle, Richard A. , Ebeid, Walid , Houdek, Matthew T. , Puri, Ajay , Brennan, Bernadette , Laitinen, Minna , Jutte, Paul C. , Lazarides, Alexander L. , Verspoor, F.G.M. , Visgauss, Julia D. , Jeys, Lee M , Morris, Guy V , Kurisunkal, Vineet , Botello, Eduardo , Ebeid, Walid , Houdek, Matthew T , Puri, Ajay , Ruggieri, Pietro , Brennan, Bernadette , Laitinen, Minna K , Couch, Cory , Rose, Peter, Sullivan, Mikaela, Tibbo, Meagan, Jutte, Paul , Visgauss, Julia D , Jeys, Lee , Ruggieri, Pietro

Mayo Clinic

The Bone & Joint Journal | February 1, 2025 | Volume: 107-B | Issue: 2 | Pages: 246-252

10.1302/0301-620x.107b2.bjj-2024-0643.r1 | PMID 39889743 Get It

AimsThe Birmingham Orthopaedic Oncology Meeting (BOOM), held in January 2024, convened 309 delegates from 53 countries to discuss and refine 21 consensus statements on the optimal management of chondrosarcoma.MethodsWith representation from Europe (43%; n = 133), North America (17%; n = 53), South America (16%; n = 49), Asia (13%; n = 40), Australasia (5%; n = 16), the Middle East (4%; n = 12), and Africa (2%; n = 6), the combined experience of treating bone sarcomas among attendees totalled approximately 30,000 cases annually, equivalent to 66 years of experience in the UK alone. The meeting’s process began with the formation of a local organizing committee, regional leads, and a scientific committee comprising representatives from 150 specialist units across 47 countries. Supported by major orthopaedic oncology organizations, the meeting used a modified Delphi process to develop consensus statements through online questionnaires, thematic groupings, narrative reviews, and anonymous pre-meeting polling.ResultsStrong (> 80%) consensus was achieved on 19 out of 21 statements, reflecting agreement among delegates. Key areas of consensus included the role of radiology in diagnosis and surveillance, the management of locally recurrent disease, and the treatment of dedifferentiated chondrosarcoma. Notably, there was agreement that routine chemotherapy has no role in chondrosarcoma treatment, and radiological surveillance is safe for intraosseous chondrosarcomas. Despite the overall consensus, areas of controversy remain, particularly regarding the treatment of atypical cartilage tumours and surgical margins. These unresolved issues underscore the need for further research and collaboration within the orthopaedic oncology community.ConclusionBOOM represents the largest global consensus meeting in orthopaedic oncology, providing valuable guidance for clinicians managing chondrosarcoma worldwide. The consensus statements offer a reference for clinical practice, highlight key research priorities, and aim to improve patient outcomes on a global scale.Cite this article: Bone Joint J 2025;107-B(2):246–252.
The effect of radiation or chemotherapy on the local recurrence, overall survival, and distant metastasis in patients with myxofibrosarcoma: A systematic review
Tibbo, Meagan E. , Landau, Rebecca , Markowitz, Moses I. , Abuodeh, Yousef , Temple, H. Thomas , Crawford, Brooke , Abuodeh, Yousef

Mayo Clinic

Journal of Surgical Oncology | August 19, 2024 | Volume: 130 | Issue: 3 | Pages: 586-593

10.1002/jso.27782 | PMID 39155707 Get It

AbstractBackground and ObjectivesManagement of myxofibrosarcoma (MFS) is widely debated, and there is no consensus regarding the effect of adjuvant therapies on local recurrence (LR), distant metastasis (DM), or overall survival (OS). This study aims to determine the effect of adjuvant therapies on the aforementioned outcomes in patients with MFS.MethodsWe conducted a systematic review via Medline, PubMed, CINAHL, Cochrane, Embase, and Google Scholar. Therapeutic studies that reported LR, DM, and OS following adjuvant therapies in patients with MFS were included. Statistical analysis and creation of hazard ratios were performed using Revman 5.3 (Cochrane Collaboration).ResultsWe identified 301 studies, 10 of which were included in the final analysis. Neither chemotherapy nor radiation affected the rate of LR (p = 0.73 and 0.17, respectively) or OS (p = 0.97 and 0.27, respectively). Chemotherapy was significantly associated with lower rates of DM (p = 0.03); however, there was no association between radiation and DM (p = 0.67).ConclusionThere is a lack of consensus regarding the effect of neoadjuvant and adjuvant therapies on LR, DM, and OS in patients with MFS. Our systematic review found that radiation and chemotherapy were not significantly associated with OS or LR in patients with MFS. However, we identified a significant association between chemotherapy and lower rates of DM.
Bedside hip aspiration results in decrease in total general anesthesia time in pediatric patients: A multicenter study
Braig, Zachary V. , Pradhan, Pratik , Tibbo, Meagan E. , Padua, Horacio M. , Shaughnessy, William J. , Stans, Anthony A. , Milbrandt, Todd A. , Padua, Horacio , Larson, A. Noelle , Shore, Benjamin J.

Mayo Clinic

Journal of Children's Orthopaedics | November 2, 2022 | Volume: 16 | Issue: 6 | Pages: 512-518

10.1177/18632521221135191 | PMID 36483652 Get It

Purpose: The purpose of this study is to compare pediatric hip aspiration in the operating room under general anesthesia or via bedside aspiration under moderate sedation and delineate the anesthetic time required. Methods: A database query conducted at two academic institutions identified all patients under the age of 17 who underwent hip aspiration between 2000 and 2017. At one institution, aspiration was performed in the operating room under general anesthesia. Patients were kept anesthetized until cell count was complete. At the second institution, aspiration was performed in the emergency room at bedside under sedation. The medical record was reviewed for demographic data, hip aspiration results, diagnoses, treatment, and anesthesia time. Results: A total of 233 patients (233 hips) with a mean age of 7.2 years were identified. Seventy-five patients underwent aspiration in the operating room, and 158 patients underwent bedside aspiration. Patients with a negative aspiration averaged 87 min under anesthesia when performed in the operating room and 29 min under sedation when performed at bedside. Patients with a negative aspiration performed in the operating room after 5 pm averaged 99 min under anesthesia, and 73 min under anesthesia when performed between 7 am and 5 pm (p < 0.01). Seventy-eight (49%) patients who underwent bedside aspiration did not require operative intervention and therefore avoided general anesthesia. Conclusion: Pediatric hip aspiration performed in the operating room results in prolonged anesthesia times while synovial fluid is transported and processed. Anesthesia times are significantly longer after 5 pm. Bedside aspiration resulted in significantly less anesthesia exposure, with half of patients undergoing bedside aspiration avoiding general anesthesia altogether. Level of evidence: Level III.
Analysis of 101 Mechanical Failures in Distal Femur Fractures Treated with 3 Generations of Precontoured Locking Plates
Collinge, Cory A. , Reeb, Alexander Francis, Rodriguez-Buitrago, Andres , Archdeacon, Michael T. , Beltran, Michael J. , Jeray, Kyle J. , Miller, Anna N. , Sems, S.A. , Shah, Nihar S. , Fogel, Nathaniel , Tibbo, Meagan E. , Tibbo, Meagan, Gardner, Michael J. , Crist, Brett D.

Mayo Clinic

Journal of Orthopaedic Trauma | July 21, 2022 | Volume: 37 | Issue: 1 | Pages: 8-13

10.1097/bot.0000000000002460 | PMID 35862769 Get It

Objectives: To evaluate mechanical treatment failure in a large patient cohort sustaining a distal femur fracture treated with a distal femoral locking plate (DFLP). Design: This retrospective case–control series evaluated mechanical treatment failures of DFLPs. Setting: The study was conducted at 8 Level I trauma centers from 2010 to 2017. Patients and Participants: One hundred one patients sustaining OTA/AO 33-A and C distal femur fractures were treated with DFLPs that experienced mechanical failure. Intervention: The intervention included the treatment of a distal femur fracture with a DFLP, affected by mechanical failure (implant failure by loosening or breakage). Main Outcome Measure: The main outcome measures included injury and DFLP details; modes and timing of failure were studied. Results: One hundred forty-six nonunions were found overall (13.4%) including 101 mechanical failures (9.3%). Failures occurred in different manners, locations, and times depending on the DFLPs. For example, 33 of 101 stainless steel (SS) plates (33%) failed by bending or breaking in the working length, whereas no Ti plates failed here ( P < 0.05). Eleven of 12 failures with titanium-Less Invasive Stabilization System (92%) occurred by lost shaft fixation, mostly by the loosening of unicortical screws (91%). Sixteen of 44 variable –angled–LCP failures (36%) occurred at the distal plate–screw junction, whereas only 5 of 61 other DFLPs (8%) failed this way ( P < 0.05). Distal failures occurred on average at 23.7 weeks compared with others that occurred at 38.4 weeks ( P < 0.05). Variable –angled–LCP distal screw–plate junction failures occurred earlier (mean 21.4 weeks). Conclusion: Nonunion and mechanical failure occurred in 14% and 9% of patients, respectively, in this large series of distal femur fracture treated with a DFLP. The mode, location, presence of a prosthesis, and timing of failure varied depending on the characteristics of DFLP. This information should be used to optimize implant usage and design to prolong the period of stable fixation before potential implant failures occur in patients with a prolonged time to union. Level of Evidence: Economic Level IV. See Instructions for Authors for a complete description of levels of evidence.
Factors Affecting the Risk of Aseptic Patellar Complications in Primary TKA Performed with Cemented All-Polyethylene Patellar Resurfacing
Limberg, Afton K. , Tibbo, Meagan E. , Ollivier, Matthieu , Tammachote, Nattapol , Abdel, Matthew P. , Berry, Daniel J. , Abdel, Matthew P , Berry, Daniel J , Limberg, Afton K. , Tibbo, Meagan E. , Ollivier, Matthieu , Tammachote, Nattapol

Mayo Clinic

Journal of Bone and Joint Surgery | December 21, 2021 | Volume: 104 | Issue: 5 | Pages: 451-458

10.2106/jbjs.21.00356 | PMID 34932523 Get It

Background: Patellar complications are a consequential cause of failure of primary total knee arthroplasty (TKA). The purpose of this study was to evaluate the association of demographic and patient factors with the long-term risk of patellar complications as a function of time in a very large cohort of primary TKAs performed with patellar resurfacing. Methods: We identified 27,192 primary TKAs utilizing cemented all-polyethylene patellar components that were performed at a single institution from 1977 through 2015. We evaluated the risk of any aseptic patellar complication and any aseptic patellar reoperation or revision, subanalyzed risks of reoperation or revision for loosening, maltracking/instability, and wear, and evaluated the risk of clinical diagnosis of patellar fracture and clunk/crepitus. The mean age at TKA was 68 years (range, 18 to 99 years); 57% of the patients were female. The mean body mass index (BMI) was 32 kg/m 2 . The primary diagnosis was osteoarthritis in 83%, and 70% of the TKAs were posterior-stabilized. Median follow-up was 7 years (range, 2 to 40 years). Risk factors for each outcome were evaluated with Cox regression models. Results: Nine hundred and seventy-seven knees with all-polyethylene patellae developed patellar complications. Survivorship free from any aseptic patellar complication was 93.3% at 20 years. Twenty-year survivorship free from any aseptic patellar reoperation was 97.3% and free from any aseptic patellar revision was 97.4%. Fifteen-year survivorship for the same end points for procedures performed from 2000 to 2015 was 95.7%, 99.2% and 99.3% respectively, representing substantial improvements compared with implants placed before 2000. Univariate analysis demonstrated that male sex (hazard ratio [HR], 1.4), an age of <65 years (HR, 1.3), and a BMI of ≥30 kg/m 2 (HR, 1.2) were associated with increased risk of patellar complications (all p ≤0.01). Posterior-stabilized designs were associated with fewer patellar reoperations and revisions overall (HR, 0.4 and 0.4; p < 0.001) but higher risk of patellar clunk/crepitus (HR, 14.1; p < 0.001). Conclusions: The 20-year survivorship free from any aseptic patellar complication in this series of cemented all-polyethylene patellae was 93%. Important risk factors for any aseptic patellar complication were male sex, an age of <65 years, a BMI of ≥30 kg/m 2 , and a patella implanted before 2000. Level of Evidence: Prognostic Level IV . See Instructions for Authors for a complete description of levels of evidence.
Outcomes of operatively treated interprosthetic femoral fractures
Tibbo, Meagan E. , Limberg, Afton K. , Huang, Phil, Perry, Kevin I. , Berry, Daniel J. , Gausden, Elizabeth B. , Yuan, Brandon J. , Berry, Daniel J , Abdel, Matthew P.

Mayo Clinic

The Bone & Joint Journal | July 1, 2021 | Volume: 103-B | Issue: 7 Supple B | Pages: 122-128

10.1302/0301-620x.103b7.bjj-2020-2275.r1 | PMID 34192901 Get It

AimsThe prevalence of ipsilateral total hip arthroplasty (THA) and total knee arthroplasty (TKA) is rising in concert with life expectancy, putting more patients at risk for interprosthetic femur fractures (IPFFs). Our study aimed to assess treatment methodologies, implant survivorship, and IPFF clinical outcomes.MethodsA total of 76 patients treated for an IPFF from February 1985 to April 2018 were reviewed. Prior to fracture, at the hip/knee sites respectively, 46 femora had primary/primary, 21 had revision/primary, three had primary/revision, and six had revision/revision components. Mean age and BMI were 74 years (33 to 99) and 30 kg/m2(21 to 46), respectively. Mean follow-up after fracture treatment was seven years (2 to 24).ResultsOverall, 59 fractures were classified as Vancouver C (Unified Classification System (UCS) D), 17 were Vancouver B (UCS B). In total, 57 patients (75%) were treated with open reduction and internal fixation (ORIF); three developed nonunion, three developed periprosthetic joint infection, and two developed aseptic loosening. In all, 18 patients (24%) underwent revision arthroplasty including 13 revision THAs, four distal femoral arthroplasties (DFAs), and one revision TKA: of these, one patient developed aseptic loosening and two developed nonunion. Survivorship free from any reoperation was 82% (95% confidence interval (CI) 66.9% to 90.6%) and 77% (95% CI 49.4% to 90.7%) in the ORIF and revision groups at two years, respectively. ORIF patients who went on to union tended to have stemmed knee components and greater mean interprosthetic distance (IPD = 189 mm (SD 73.6) vs 163 mm (SD 36.7); p = 0.546) than nonunited fractures. Patients who went on to nonunion in the revision arthroplasty group had higher medullary diameter: cortical width ratio (2.5 (SD 1.7) vs 1.3 (SD 0.3); p = 0.008) and lower IPD (36 mm (SD 30.6) vs 214 mm (SD 32.1); p < 0.001). At latest follow-up, 95% of patients (n = 72) were ambulatory.ConclusionInterprosthetic femur fractures are technically and biologically challenging cases. Individualized approaches to internal fixation versus revision arthroplasty led to an 81% (95% CI 68.3% to 88.6%) survivorship free from reoperation at two years with 95% of patients ambulatory. Continued improvements in management are warranted. Cite this article: Bone Joint J 2021;103-B(7 Supple B):122–128.